Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting now · Phase 2

Conditions studied: Hematological Malignancy, Neutropenia

In brief

Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound neutropenia (ANC\<100 neutrophils/milliliter) for more than seven days. Xerava™ (eravacycline) has a broad spectrum of activity including many multi-drug resistant strains of bacteria. It is not an agent used for treatment of febrile neutropenia, making eravacycline a very attractive alternative to consider in this prophylactic setting. Eravacycline has activity against MRSA, VRE, and Clostridioides difﬁcile, all of which are common problems in this patient population. It also covers the majority of enteric gram-negative pathogens while also producing satisfactory tissue penetration and adequate plasma concentrations, which has classically been a concern with prior agents. Eravacycline has activity against coagulase-negative staphylococcus, which is a common catheter-related infection in leukemia and HSCT patients. The primary objective will be report the incidence of breakthrough infections during eravacycline prophylaxis for hematologic malignancy patients with prolonged neutropenia.

Key facts

Study ID: NCT05537896
Run by: West Virginia University
People needed: 55
Starts: 2024-02-19
Expected to finish: 2028-02-01
Last updated by the study team: 2026-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

All patients receiving induction chemotherapy for treatment of acute leukemia or receiving preparative regimen for HSCT
Patient must provide informed consent.
Bilirubin ≤ 3 x the ULN and AST/ALT ≤ 5 x ULN

You may not qualify if…

Uncontrolled bacterial, viral or fungal infection at the time of study enrollment.
Urinary tract infection receiving active treatment
Acute pancreatitis (not necessary to work-up unless symptomatic)
History of known hypersensitivity to eravacycline, tetracycline, doxycycline, minocycline, tigecycline, sarecycline, oxytetracycline, or omadacycline
Pseudomonas infection within 30 days prior to study enrollment
Receiving strong inhibitors or inducers of cytochrome P450 3A4 will be excluded from the study (see Appendix B for complete list of medications)
Pregnant or lactating women

Where it is running

Aaron Cumpston — Morgantown, West Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.